Compare Monolithic Power Systems Inc (MPWR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Summit Therapeutics Inc — how do they compare? Monolithic Power Systems Inc trades at $1,417.02 (market cap $70.03B), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Monolithic Power Systems Inc is far larger — about 5.8× Summit Therapeutics Inc's market cap, and Monolithic Power Systems Inc pays a 0.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPWR | SMMT | |
|---|---|---|
Market Cap | $70.03B | $12.06B |
Sector | Utilities | Health |
52-Week High | $1.69K | $26.98 |
52-Week Low | $820.74 | $12.55 |
Enterprise Value | $68.63B | $11.39B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.01, up 3.18% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, supported by AI-driven revenue growth. Recent news highlights legal scrutiny but also analyst optimism post-Q2 results.
Outlook is positive with an 88% buy rating from analysts and a $1,870 consensus price target, though high valuation ratios and competitive risks warrant caution. Upside hinges on continued AI infrastructure demand, while downside risks include execution challenges and market volatility.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
